Advertisement

Topics

Eisai Co., Ltd Company Profile

17:54 EST 20th November 2017 | BioPortfolio

A human health care company capable of making a meaningful contribution under any health care system while observing the highest legal and ethical standards in business activities.We give first thought to patients and their families, and to increasing the benefits health care provides

Location

4-6-10 Koishikawa, Bunkyo-ku
Tokyo
112-8088
Japan

Contact

Phone: 81-3-3817-3700


News Articles [141 Associated News Articles listed on BioPortfolio]

Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America

TOKYO, Oct 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology an...

Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December

Following Agreement with National Association of Statutory Health Insurance Funds TOKYO, Nov 20, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that its German sales company Eisai GmbH (Loca...

Eisai, Biotoscana ink exclusive licensing pact for Latin America

Eisai announced that its US subsidiary, Eisai, has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America.

Ono and Eisai focus on hepatocellular carcinoma in new trial collaboration

Eisai Co. Ltd. partnered with Ono Pharmaceutical Co. Ltd. to develop a hepatocellular carcinoma therapy combining Eisai’s Lenvima (lenvatinib) with Ono’s Opdivo (nivolumab).

FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-onset Seizures

July 27, 2017 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that on July 26, 2017 (U.S. time), its U.S. subsidiary Eisai Inc. received approval from the U.S. Food...

Biogen and Eisai Expand Collaboration for Development of Aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, Un...

Eisai enters license deals for Latin America and Japan

Eisai’s US subsidiary has signed an exclusive licensing agreement with Uruguay-headquartered Grupo…

FDA Approves Second Indication for Eisai's Monotherapy, Treating Partial-Onset Seizures

NewsFDA approves Eisai's FYCOMPA® (perampanel) for use as monotherapy for the treatment of partial-onset seizures.

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Halaven [Eisai Inc.]

These highlights do not include all the information needed to use HALAVEN™ safely and effectively. See full prescribing information for HALAVEN. HALAVEN™ (eribulin mesylate) Injection For intraven...

Lusedra [Eisai, Inc]

These highlights do not include all the information needed to use LUSEDRA safely and effectively. See full prescribing information for LUSEDRA. LUSEDRA (fospropofol disodium) Injection, for intravenou...

Ontak [Eisai, Inc]

These highlights do not include all the information needed to use Ontak safely and effectively. See full prescribing information for Ontak. ONTAK (denileukin diftitox) Injection for intravenous infusi...

Hexalen [Eisai Inc.]

HEXALEN (ALTRETAMINE) CAPSULES 50 mg R Only

Targretin [Eisai Inc.]

Targretin® (bexarotene) capsules, 75 mg

PubMed Articles [0 Results]

None

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA...

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets to Eisai's Aciphex® delayed-release 20 mg tablets following a...

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union (EU) for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of ...

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is cond...

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Treatment of triple negative breast cancer (TNBC) relies heavily on different regimes of chemotherapeutic agents but remains one of the most challenging subtypes to treat because of the la...

Companies [14 Associated Companies listed on BioPortfolio]

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Co., Ltd" on BioPortfolio

We have published hundreds of Eisai Co., Ltd news stories on BioPortfolio along with dozens of Eisai Co., Ltd Clinical Trials and PubMed Articles about Eisai Co., Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Co., Ltd Companies in our database. You can also find out about relevant Eisai Co., Ltd Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record